Skip to main content
Clinical Trials/EUCTR2005-000480-25-FI
EUCTR2005-000480-25-FI
Active, not recruiting
Not Applicable

Classification and characterization of patient suffering from moderate to severe plaque psoriasis responding to subcutaneous administered efalizumab - ROCAC

Investigator Trondheim Hudlegesenter AS0 sites150 target enrollmentStarted: June 19, 2006Last updated:

Overview

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Investigator Trondheim Hudlegesenter AS
Enrollment
150

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • The study population consists of patients of both genders, over the age of 18 years who have been suffering from stable moderate to severe plaque psoriasis for more than six months and who are eligible for efalizumab treatment according to current national guidelines, i.e. the patients have not responded to, have contraindications to or are intolerant to other systemic treatment, including cyklosporin, methotrexat and PUVA.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \* Pregnant or breast\-feeding patients.
  • \* Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
  • \* Patients suffering from HIV, hepatitis B and C, active tuberculosis (TB) or currently undergoing treatment for TB, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.
  • \* Patients with history of cancer in the preceding 5 years, including lymphproliferative disorders. Patients with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
  • \* Patients to whom subcutaneous administered efalizumab treatments are contraindicated.

Investigators

Sponsor
Investigator Trondheim Hudlegesenter AS

Similar Trials